Routine Anticoagulation Seems Warranted After TMVR: Review
(UPDATED) Evidence on the risk of valve thrombosis and the best way to manage it is still limited, however.
Related Articles
2025 SCAI Scientific Sessions
The 2025 SCAI Scientific Sessions will be held May 1st-3rd, 2025 in Washington, DC. Login to view Sessions and Papers saved as favorites. View schedules,…
SCAI Joins in Support of New Prior Authorization Reform Bill | SCAI
In collaboration with the other members of the Regulatory Relief Coalition (RRC), SCAI has written to Senators Green, Murphy, and Schrier, thanking them for their…
Mentor Connect | SCAI
The SCAI’s Mentor Connect program is a community-building initiative and professional development opportunity for all participating interventional cardiologists. For a mentor, this is your opportunity…
SCAI Renal Denervation Regional Course—Houston 2025 | SCAI
High blood pressure is a leading risk factor for heart disease and stroke, affecting nearly half of US adults and contributing to 685,875 deaths in…
CMS Releases Proposed Decision Memo for Tricuspid TEER
The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.
Boston Scientific India EDUCARE: HealConclave—Form and Function | SCAI
SCAI and Boston Scientific India Educare are pleased to announce the continuation of the leading-edge webinar series HealConclave: Form & Function. This series has been…
New Statement for Public Comment | SCAI
SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions. Feedback is requested by October 16th. The Society for Cardiovascular Angiography and Interventions is…
SCAI Renal Denervation Regional Course—Houston 2025 | SCAI
High blood pressure is a leading risk factor for heart disease and stroke, affecting nearly half of US adults and contributing to 685,875 deaths in…